Literature DB >> 19467991

Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome.

James R Connor1, Xin-Sheng Wang, Richard P Allen, John L Beard, Jason A Wiesinger, Barbara T Felt, Christopher J Earley.   

Abstract

Restless leg syndrome (RLS) is a sensorimotor disorder. Clinical studies have implicated the dopaminergic system in RLS, while others have suggested that it is associated with insufficient levels of brain iron. To date, alterations in brain iron status have been demonstrated but, despite suggestions from the clinical literature, there have been no consistent findings documenting a dopaminergic abnormality in RLS brain tissue. In this study, the substantia nigra and putamen were obtained at autopsy from individuals with primary RLS and a neurologically normal control group. A quantitative profile of the dopaminergic system was obtained. Additional assays were performed on a catecholaminergic cell line and animal models of iron deficiency. RLS tissue, compared with controls, showed a significant decrease in D2R in the putamen that correlated with severity of the RLS. RLS also showed significant increases in tyrosine hydroxylase (TH) in the substantia nigra, compared with the controls, but not in the putamen. Both TH and phosphorylated (active) TH were significantly increased in both the substantia nigra and putamen. There were no significant differences in either the putamen or nigra for dopamine receptor 1, dopamine transporters or for VMAT. Significant increases in TH and phosphorylated TH were also seen in both the animal and cell models of iron insufficiency similar to that from the RLS autopsy data. For the first time, a clear indication of dopamine pathology in RLS is revealed in this autopsy study. The results suggest cellular regulation of dopamine production that closely matches the data from cellular and animal iron insufficiency models. The results are consistent with the hypothesis that a primary iron insufficiency produces a dopaminergic abnormality characterized as an overly activated dopaminergic system as part of the RLS pathology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19467991      PMCID: PMC2732265          DOI: 10.1093/brain/awp125

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  40 in total

1.  Opioid and dopamine antagonist drug challenges in untreated restless legs syndrome patients.

Authors: 
Journal:  Sleep Med       Date:  2001-01       Impact factor: 3.492

2.  Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies.

Authors:  N Turjanski; A J Lees; D J Brooks
Journal:  Neurology       Date:  1999-03-23       Impact factor: 9.910

Review 3.  Clinical practice. Restless legs syndrome.

Authors:  Christopher J Earley
Journal:  N Engl J Med       Date:  2003-05-22       Impact factor: 91.245

4.  Chronic high dose L-dopa treatment does not alter the levels of dopamine D-1, D-2 or D-3 receptor in the striatum of normal monkeys: an autoradiographic study.

Authors:  B Y Zeng; R K Pearce; G M MacKenzie; P Jenner
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

5.  CSF dopamine, serotonin, and biopterin metabolites in patients with restless legs syndrome.

Authors:  C J Earley; K Hyland; R P Allen
Journal:  Mov Disord       Date:  2001-01       Impact factor: 10.338

6.  Computerized movement analysis and beta-CIT-SPECT in patients with restless legs syndrome.

Authors:  M Mrowka; M Jöbges; G Berding; N Schimke; M Shing; P Odin
Journal:  J Neural Transm (Vienna)       Date:  2004-10-27       Impact factor: 3.575

Review 7.  Iron deficiency alters brain development and functioning.

Authors:  John Beard
Journal:  J Nutr       Date:  2003-05       Impact factor: 4.798

8.  Normal dopaminergic and serotonergic metabolites in cerebrospinal fluid and blood of restless legs syndrome patients.

Authors:  Karin Stiasny-Kolster; J Carsten Möller; Johannes Zschocke; Oliver Bandmann; Werner Cassel; Wolfgang H Oertel; Georg F Hoffmann
Journal:  Mov Disord       Date:  2004-02       Impact factor: 10.338

9.  Neuropathology of primary restless leg syndrome: absence of specific tau- and alpha-synuclein pathology.

Authors:  Sean J Pittock; Timothy Parrett; Charles H Adler; Joseph E Parisi; Dennis W Dickson; J Eric Ahlskog
Journal:  Mov Disord       Date:  2004-06       Impact factor: 10.338

10.  Iron deficiency in rats decreases acquisition of and suppresses responding for cocaine.

Authors:  Byron C Jones; Daniel S Wheeler; John L Beard; Patricia Sue Grigson
Journal:  Pharmacol Biochem Behav       Date:  2002-11       Impact factor: 3.533

View more
  112 in total

Review 1.  Restless legs syndrome: pathophysiology, clinical presentation and management.

Authors:  Claudia Trenkwalder; Walter Paulus
Journal:  Nat Rev Neurol       Date:  2010-06       Impact factor: 42.937

Review 2.  Update in restless legs syndrome.

Authors:  Rachel E Salas; Charlene E Gamaldo; Richard P Allen
Journal:  Curr Opin Neurol       Date:  2010-08       Impact factor: 5.710

Review 3.  Caenorhabditis elegans and its applicability to studies on restless legs syndrome.

Authors:  Pan Chen; Omamuyovwi Meashack Ijomone; Kun He Lee; Michael Aschner
Journal:  Adv Pharmacol       Date:  2019-03-14

4.  Characterization of extrastriatal D2 in vivo specific binding of [¹⁸F](N-methyl)benperidol using PET.

Authors:  Sarah A Eisenstein; Jon M Koller; Marilyn Piccirillo; Ana Kim; Jo Ann V Antenor-Dorsey; Tom O Videen; Abraham Z Snyder; Morvarid Karimi; Stephen M Moerlein; Kevin J Black; Joel S Perlmutter; Tamara Hershey
Journal:  Synapse       Date:  2012-05-15       Impact factor: 2.562

5.  Restless legs syndrome in multiple system atrophy.

Authors:  Imad Ghorayeb; Sandrine Dupouy; François Tison; Wassilios G Meissner
Journal:  J Neural Transm (Vienna)       Date:  2014-05-13       Impact factor: 3.575

6.  Hyperactivity, dopaminergic abnormalities, iron deficiency and anemia in an in vivo opioid receptors knockout mouse: Implications for the restless legs syndrome.

Authors:  Shangru Lyu; Mark P DeAndrade; Stefan Mueller; Alexander Oksche; Arthur S Walters; Yuqing Li
Journal:  Behav Brain Res       Date:  2019-07-31       Impact factor: 3.332

Review 7.  Animal models of sleep disorders.

Authors:  Linda A Toth; Pavan Bhargava
Journal:  Comp Med       Date:  2013-04       Impact factor: 0.982

8.  BTBD9 and dopaminergic dysfunction in the pathogenesis of restless legs syndrome.

Authors:  Shangru Lyu; Atbin Doroodchi; Hong Xing; Yi Sheng; Mark P DeAndrade; Youfeng Yang; Tracy L Johnson; Stefan Clemens; Fumiaki Yokoi; Michael A Miller; Rui Xiao; Yuqing Li
Journal:  Brain Struct Funct       Date:  2020-05-28       Impact factor: 3.270

9.  Multimodal MR imaging of brain iron in attention deficit hyperactivity disorder: a noninvasive biomarker that responds to psychostimulant treatment?

Authors:  Vitria Adisetiyo; Jens H Jensen; Ali Tabesh; Rachael L Deardorff; Els Fieremans; Adriana Di Martino; Kevin M Gray; Francisco X Castellanos; Joseph A Helpern
Journal:  Radiology       Date:  2014-06-17       Impact factor: 11.105

10.  Iron-deficiency and dopaminergic treatment effects on RLS-Like behaviors of an animal model with the brain iron deficiency pattern of the restless legs syndrome.

Authors:  Richard P Allen; Christopher J Earley; Byron C Jones; Erica L Unger
Journal:  Sleep Med       Date:  2020-02-05       Impact factor: 3.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.